Evolution of the clinical manifestations of infection during the course of febrile neutropenia in patients with malignancy

被引:6
|
作者
Dompeling, EC
Donnelly, JP
Raemaekers, JMM
Deresinski, SC
Feld, R
De Pauw, BE
机构
[1] Univ Nijmegen St Radboud Hosp, Div Hematol, NL-6500 HB Nijmegen, Netherlands
[2] Univ Nijmegen St Radboud Hosp, Inst Med Microbiol, NL-6500 HB Nijmegen, Netherlands
[3] Stanford Univ, Sch Med, Redwood City, CA 94062 USA
[4] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada
关键词
D O I
10.1007/BF02770834
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
The impact of a standardized set of diagnostic interventions on the further management of 968 episodes of fever in neutropenic cancer patients who did not respond to initial therapy was assessed prospectively. At the onset of fever, 65% of patients had no additional signs of infection, whereas skin and soft tissue infections were present in 12%, and clinical sepsis and gastrointestinal infections in 8% each. After 72 h, 41% of the fevers still remained unexplained. New foci of infection emerged in 11% of the cases involving mainly the lungs, skin and soft tissues, and urinary tract, The presence of a lower respiratory tract infection or a microbiologically defined infection of any sort was associated with higher mortality than other types of infection were, Changes in initial antibiotic therapy were based on the results of the diagnostic measures specified in the protocol in only 15% of the cases.
引用
收藏
页码:349 / 354
页数:6
相关论文
共 50 条
  • [31] Assessment of procalcitonin as a diagnostic marker of underlying infection in patients with febrile neutropenia
    Giamarellos-Bourboulis, EJ
    Grecka, P
    Poulakou, G
    Anargyrou, K
    Katsilambros, N
    Giamarellou, H
    CLINICAL INFECTIOUS DISEASES, 2001, 32 (12) : 1718 - 1725
  • [32] Evaluation of Using Empiric Glycopeptides in Accordance with the IDSA Guidelines in Hematologic Malignancy Patients with Febrile Neutropenia
    Yalcin, Cumali
    Ozkalemkas, Fahir
    Ozkocaman, Vildan
    Ersal, Tuba
    Pinar, Ibrahim Ethem
    Orhan, Bedrettin
    Candar, Omer
    Cubukcu, Sinem
    Koca, Tuba Gullu
    Akyol, Merve Nur
    Ada, Nevriye Gul
    Ozakin, Cuneyt
    Kazak, Esra
    Akalin, Halis
    Ali, Ridvan
    MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES, 2022, 14
  • [33] Altered Pharmacokinetics Parameters of Vancomycin in Patients with Hematological Malignancy with Febrile Neutropenia, a Bayesian Software Estimation
    Alzahrani, Abdullah M.
    Naeem, Anjum
    AlAzmi, Aeshah
    Hakami, Alqassem Y.
    Karim, Shahid
    Ali, Ahmed S.
    Kamel, Fatemah Omer
    Alzhrani, Rami M.
    Alkhaldi, Teaf S.
    Maghrabi, Loujayne A.
    Alshehri, Norah F.
    Alzahrani, Yahya A.
    ANTIBIOTICS-BASEL, 2023, 12 (06):
  • [34] Plasma presepsin level is an early diagnostic marker of severe febrile neutropenia in hematologic malignancy patients
    Koizumi, Yusuke
    Shimizu, Kaoru
    Shigeta, Masayo
    Okuno, Takafumi
    Minamiguchi, Hitoshi
    Kito, Katsuyuki
    Hodohara, Keiko
    Yamagishi, Yuka
    Andoh, Akira
    Fujiyama, Yoshihide
    Mikamo, Hiroshige
    BMC INFECTIOUS DISEASES, 2017, 17
  • [35] Plasma presepsin level is an early diagnostic marker of severe febrile neutropenia in hematologic malignancy patients
    Yusuke Koizumi
    Kaoru Shimizu
    Masayo Shigeta
    Takafumi Okuno
    Hitoshi Minamiguchi
    Katsuyuki Kito
    Keiko Hodohara
    Yuka Yamagishi
    Akira Andoh
    Yoshihide Fujiyama
    Hiroshige Mikamo
    BMC Infectious Diseases, 17
  • [36] Clinical and laboratory evolution of the febrile neutropenia episodes in pediatric patients hospitalized in a Colombian hospital in 2007-2009
    Hurtado, Isabel C.
    Sanchez, Diana P.
    Espinal, David A.
    Garces, Carlos
    REVISTA CHILENA DE INFECTOLOGIA, 2012, 29 (06): : 672 - 676
  • [37] A retrospective analysis to estimate target trough concentration of vancomycin for febrile neutropenia in patients with hematological malignancy
    Suzuki, Yosuke
    Tokimatsu, Issei
    Morinaga, Yuko
    Sato, Yuhki
    Takano, Kuniko
    Kohno, Kazuhiro
    Ogata, Masao
    Hiramatsu, Kazufumi
    Itoh, Hiroki
    Kadota, Jun-ichi
    CLINICA CHIMICA ACTA, 2015, 440 : 183 - 187
  • [38] Acute kidney injury incidence in patients with hematological malignancy treated with meropenem and vancomycin for febrile neutropenia
    Kobayashi, Shunsuke
    Yasu, Takeo
    Momo, Kenji
    CLINICAL NEPHROLOGY, 2019, 91 (06) : 392 - 394
  • [39] Therapeutic Drug Monitoring of Teicoplanin in Haematological Malignancy Patients with Febrile Neutropenia and Optimizing Dosage Regimens
    Hu, Sasa
    Wang, Taotao
    You, Haisheng
    Wei, Shuangyu
    Song, Hongjuan
    Zhang, Tao
    Zhang, Di
    Dong, Yalin
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2018, 123 (05) : 594 - 601
  • [40] Efficacy of piperacillin/tazobactam as initial empiric therapy of febrile neutropenia in patients with hematologic malignancy.
    Bow, EJ
    Noskin, GA
    Schwarer, AP
    Laverdiere, M
    Vesole, DH
    BLOOD, 2003, 102 (11) : 281A - 281A